Other authors have tested the possibility to activate anti-CLL NK cell cytotoxicity through the engagement of NKG2D by a new construct, namely ULBP2/aCD19/aCD19, a trispecific immunoligand containing ULBP2 as a natural ligand for NKG2D receptor on NK cells and two sets of a CD19-specific scFv (aCD19) to target CLL cells [248]. Here, KLRK1 is linked to B-cell chronic lymphocytic leukemia.